{"id":56196,"date":"2026-02-03T22:23:50","date_gmt":"2026-02-03T14:23:50","guid":{"rendered":"https:\/\/flcube.com\/?p=56196"},"modified":"2026-02-03T22:23:52","modified_gmt":"2026-02-03T14:23:52","slug":"insilico-medicine-doses-first-patient-in-men2501-phase-i-triggers-5m-menarini-milestone","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56196","title":{"rendered":"Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone"},"content":{"rendered":"\n<p><strong>Insilico Medicine<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3696:HKG\">HKG: 3696<\/a>) announced the first patient dosing in a <strong>Phase I clinical study<\/strong> for <strong>MEN2501<\/strong>, a <strong>KIF18A inhibitor<\/strong> out\u2011licensed to <strong>Menarini Group<\/strong>. The milestone triggered a <strong>HKD\u202f39\u202fmillion (USD\u202f5\u202fmillion)<\/strong> payment from the Italian company under a prior <strong>USD\u202f550\u202fmillion<\/strong> licensing agreement.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-milestone-amp-deal-structure\">Milestone &amp; Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Insilico Medicine (3696.HK)<\/td><\/tr><tr><td><strong>Partner<\/strong><\/td><td>Menarini Group (via Temline Therapeutics subsidiary)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>MEN2501 (KIF18A inhibitor)<\/td><\/tr><tr><td><strong>Milestone<\/strong><\/td><td>First patient dosed in Phase I<\/td><\/tr><tr><td><strong>Payment Triggered<\/strong><\/td><td>HKD\u202f39\u202fM (USD\u202f5\u202fM)<\/td><\/tr><tr><td><strong>Total Deal Value<\/strong><\/td><td>USD\u202f550\u202fM licensing agreement<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Inhibits KIF18A for chromosomal instability cancers<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-technology\">Drug Profile &amp; Technology<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> KIF18A, a kinesin protein critical for chromosome segregation in cancers with high chromosomal instability<\/li>\n\n\n\n<li><strong>Preclinical Data:<\/strong> Demonstrates significant inhibitory activity against chromosomal instability cancers<\/li>\n\n\n\n<li><strong>Platform:<\/strong> Developed using Insilico\u2019s generative AI drug discovery platform<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> Validates AI\u2011driven discovery for novel oncology targets; expands Menarini\u2019s oncology pipeline<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chromosomal Instability Market:<\/strong> Represents <strong>~30%<\/strong> : of solid tumors; targeted therapies offer <strong>$5\u202fbillion+<\/strong> global opportunity<\/li>\n\n\n\n<li><strong>Milestone Revenue:<\/strong> $5\u202fM payment provides near\u2011term cash; additional milestones tied to Phase II\/III progress could reach <strong>$100\u202fM+<\/strong> :<\/li>\n\n\n\n<li><strong>AI Validation:<\/strong> Successful Phase I initiation reinforces Insilico\u2019s platform credibility, potentially attracting additional partnerships<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Dose escalation ongoing; Phase I data expected <strong>H2\u202f2026<\/strong> ; Menarini to lead global development<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, milestone achievements, and revenue potential for MEN2501. Actual results may differ due to clinical trial outcomes, competitive dynamics, and regulatory review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020300090_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026020300090_c.\"><\/object><a id=\"wp-block-file--media-8444beb6-0653-4a73-b90f-5d4a21e0d099\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020300090_c.pdf\">2026020300090_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/2026020300090_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-8444beb6-0653-4a73-b90f-5d4a21e0d099\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4514,164,1047],"class_list":["post-56196","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-3696","tag-insilico-medicine","tag-menarini"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study for MEN2501, a KIF18A inhibitor out\u2011licensed to Menarini Group. The milestone triggered a HKD\u202f39\u202fmillion (USD\u202f5\u202fmillion) payment from the Italian company under a prior USD\u202f550\u202fmillion licensing agreement.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56196\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone\" \/>\n<meta property=\"og:description\" content=\"Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study for MEN2501, a KIF18A inhibitor out\u2011licensed to Menarini Group. The milestone triggered a HKD\u202f39\u202fmillion (USD\u202f5\u202fmillion) payment from the Italian company under a prior USD\u202f550\u202fmillion licensing agreement.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56196\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-03T14:23:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-03T14:23:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56196#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56196\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone\",\"datePublished\":\"2026-02-03T14:23:50+00:00\",\"dateModified\":\"2026-02-03T14:23:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56196\"},\"wordCount\":271,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 3696\",\"Insilico Medicine\",\"Menarini\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56196#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56196\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56196\",\"name\":\"Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-03T14:23:50+00:00\",\"dateModified\":\"2026-02-03T14:23:52+00:00\",\"description\":\"Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study for MEN2501, a KIF18A inhibitor out\u2011licensed to Menarini Group. The milestone triggered a HKD\u202f39\u202fmillion (USD\u202f5\u202fmillion) payment from the Italian company under a prior USD\u202f550\u202fmillion licensing agreement.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56196#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56196\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56196#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone - Insight, China&#039;s Pharmaceutical Industry","description":"Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study for MEN2501, a KIF18A inhibitor out\u2011licensed to Menarini Group. The milestone triggered a HKD\u202f39\u202fmillion (USD\u202f5\u202fmillion) payment from the Italian company under a prior USD\u202f550\u202fmillion licensing agreement.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56196","og_locale":"en_US","og_type":"article","og_title":"Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone","og_description":"Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study for MEN2501, a KIF18A inhibitor out\u2011licensed to Menarini Group. The milestone triggered a HKD\u202f39\u202fmillion (USD\u202f5\u202fmillion) payment from the Italian company under a prior USD\u202f550\u202fmillion licensing agreement.","og_url":"https:\/\/flcube.com\/?p=56196","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-03T14:23:50+00:00","article_modified_time":"2026-02-03T14:23:52+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56196#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56196"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone","datePublished":"2026-02-03T14:23:50+00:00","dateModified":"2026-02-03T14:23:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56196"},"wordCount":271,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 3696","Insilico Medicine","Menarini"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56196#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56196","url":"https:\/\/flcube.com\/?p=56196","name":"Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-03T14:23:50+00:00","dateModified":"2026-02-03T14:23:52+00:00","description":"Insilico Medicine (HKG: 3696) announced the first patient dosing in a Phase I clinical study for MEN2501, a KIF18A inhibitor out\u2011licensed to Menarini Group. The milestone triggered a HKD\u202f39\u202fmillion (USD\u202f5\u202fmillion) payment from the Italian company under a prior USD\u202f550\u202fmillion licensing agreement.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56196#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56196"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56196#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Insilico Medicine Doses First Patient in MEN2501 Phase I, Triggers $5M Menarini Milestone"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56196","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56196"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56196\/revisions"}],"predecessor-version":[{"id":56199,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56196\/revisions\/56199"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56196"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56196"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}